These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 7067372)

  • 1. Potentiation of anticoagulant response to warfarin by sulphinpyrazone: a double-blind study in patients with prosthetic heart valves.
    Girolami A; Fabris F; Casonato A; Randi ML
    Clin Lab Haematol; 1982; 4(1):23-6. PubMed ID: 7067372
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interaction of sulphinpyrazone with warfarin.
    Miners JO; Foenander T; Wanwimolruk S; Gallus AS; Birkett DJ
    Eur J Clin Pharmacol; 1982; 22(4):327-31. PubMed ID: 7106169
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potentiation of warfarin action by sulphinpyrazone.
    Bailey RR; Reddy J
    Lancet; 1980 Feb; 1(8162):254. PubMed ID: 6101699
    [No Abstract]   [Full Text] [Related]  

  • 4. Failure of sulphinpyrazone to affect platelet survival in patients with rheumatic heart valvular disease: a double blind study using 75Se-methionine labeled platelets.
    Fabris F; Casonato A; Randi ML; Schivazappa L; Schiavinato L; Girolami A
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1983; 110(4):594-601. PubMed ID: 6196274
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interference by sulphinpyrazone with the antihypertensive effects of oxprenolol.
    Ferrara LA; Mancini M; Marotta T; Pasanisi F; Fasano ML
    Eur J Clin Pharmacol; 1986; 29(6):717-9. PubMed ID: 3519237
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of sulphinpyrazone on oxidative drug metabolism in man: inhibition of tolbutamide elimination.
    Miners JO; Foenander T; Wanwimolruk S; Gallus AS; Birkett DJ
    Eur J Clin Pharmacol; 1982; 22(4):321-6. PubMed ID: 7106168
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Platelet and coagulation function in patients with abnormal cardiac valves treated with sulphinpyrazone.
    Ludlam CA; Allan N; Blandford RB; Dowdle R; Bentley NJ; Bloom AL
    Thromb Haemost; 1981 Dec; 46(4):743-6. PubMed ID: 6460338
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evidence for a dual action of sulphinpyrazone on drug metabolism in man: theophylline-sulphinpyrazone interaction.
    Birkett DJ; Miners JO; Attwood J
    Br J Clin Pharmacol; 1983 May; 15(5):567-9. PubMed ID: 6860533
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biphasic sulphinpyrazone-warfarin interaction.
    Nenci GG; Agnelli G; Berrettini M
    Br Med J (Clin Res Ed); 1981 Apr; 282(6273):1361-2. PubMed ID: 6786498
    [No Abstract]   [Full Text] [Related]  

  • 10. Sulphinpyrazone and warfarin: a probable drug interaction.
    Gallus A; Birkett D
    Lancet; 1980 Mar; 1(8167):535-6. PubMed ID: 6102248
    [No Abstract]   [Full Text] [Related]  

  • 11. A comparison of aspirin with placebo in patients treated with warfarin after heart-valve replacement.
    Turpie AG; Gent M; Laupacis A; Latour Y; Gunstensen J; Basile F; Klimek M; Hirsh J
    N Engl J Med; 1993 Aug; 329(8):524-9. PubMed ID: 8336751
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of single and multiple doses of sulphinpyrazone on antipyrine metabolism and urinary excretion of 6-beta-hydroxycortisol.
    Staiger C; Schlicht F; Walter E; Gundert-Remy U; Hildebrandt R; de Vries J; Wang NS; Harenberg J; Weber E
    Eur J Clin Pharmacol; 1983; 25(6):797-801. PubMed ID: 6141054
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Haemodynamic effects of sulphinpyrazone on exercise responses in normal subjects.
    Forfar JC; Russell DC; Oliver MF
    Lancet; 1980 Oct; 2(8197):718-20. PubMed ID: 6106828
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Does sulphinpyrazone reduce haemolysis from prosthetic heart valves?
    Errington M; Bloomfield P
    Aust N Z J Med; 1992 Aug; 22(4):382-3. PubMed ID: 1445026
    [No Abstract]   [Full Text] [Related]  

  • 15. [Picotamide does not interfere with the anticoagulant activity of warfarin in patients wearing heart valve prostheses].
    Parise P; Gresele P; Viola E; Ruina A; Migliacci R; Nenci GG
    Clin Ter; 1990 Dec; 135(6):479-82. PubMed ID: 2151435
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sulphinpyrazone and the platelet serotoninergic mechanism in ischaemic heart disease.
    Puri VK; Rawat A; Sharma A; Mehrotra A; Hasan M; Shanker K; Verma M; Sinha JN; Bhargava KP
    Br Med J (Clin Res Ed); 1986 Sep; 293(6547):591-3. PubMed ID: 3092937
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A study of the effect of sulphinpyrazone ('Anturan') on blood viscosity.
    Johnston RV; Lowe GD; Drummond MM; Forbes CD; Prentice CR
    Curr Med Res Opin; 1979; 6(4):271-3. PubMed ID: 527353
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A serial study of platelet reactivity throughout the first six months after myocardial infarction: its modification by sulphinpyrazone.
    Kubik MM; Richardson SG
    Postgrad Med J; 1987 May; 63(739):351-6. PubMed ID: 3118351
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Approaches for prescribing anticoagulant therapy to patients with prosthetic heart valves].
    Gorbunova EV
    Klin Med (Mosk); 2013; 91(2):49-52. PubMed ID: 23718066
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sulphinpyrazone in post-myocardial infarction. Report from the Anturan Reinfarction Italian Study.
    Lancet; 1982 Jan; 1(8266):237-42. PubMed ID: 6120272
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.